These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 12719922)

  • 41. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma.
    Vinnicombe SJ; Reznek RH
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S42-55. PubMed ID: 12709830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
    Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
    J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
    Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
    Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
    Weihrauch MR; Re D; Bischoff S; Dietlein M; Scheidhauer K; Krug B; Textoris F; Ansén S; Franklin J; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
    Ann Hematol; 2002 Jan; 81(1):20-5. PubMed ID: 11807631
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T; Nihashi T; Hotta T; Nagai H
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma.
    Naumann R; Beuthien-Baumann B; Reiss A; Schulze J; Hänel A; Bredow J; Kühnel G; Kropp J; Hänel M; Laniado M; Kotzerke J; Ehninger G
    Br J Cancer; 2004 Feb; 90(3):620-5. PubMed ID: 14760374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
    Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
    Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.
    Lang O; Bihl H; Hültenschmidt B; Sautter-Bihl ML
    Strahlenther Onkol; 2001 Mar; 177(3):138-44. PubMed ID: 11285771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma].
    Higuchi T
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):278-83. PubMed ID: 12073634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
    Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
    J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.